(Q42681087)

4 November 2017

title

GM1 ganglioside in the treatment of Parkinson's disease (English)

1 reference

4 November 2017

1 reference

Schneider JS

1

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

Annals of the New York Academy of Sciences

4 November 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

4 November 2017

volume

845

1 reference

4 November 2017

issue

1 SPHINGOLIPIDS

1 reference

29 June 2019

page(s)

363-373

1 reference

Ganglioside interactions with the dopaminergic system of rats

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

The functional recovery of damaged brain: The effect of GM1 monosialoganglioside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Rate of cell death in parkinsonism indicates active neuropathological process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Parkinson's disease: Sensory and motor problems in arms and hands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Distractibility in early Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

An Inventory for Measuring Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP(+)-induced damage: dependence on initial damage and time of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Effects of ganglioside treatments on lesion-induced behavioral impairments and sprouting in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

Acetylcholine release in vivo: effects of chronic treatment with monosialoganglioside GM1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

The natural history of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1998.TB09688.X

10.1111/J.1749-6632.1998.TB09688.X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference